T
Thomas Ernst
Researcher at University of Jena
Publications - 80
Citations - 5680
Thomas Ernst is an academic researcher from University of Jena. The author has contributed to research in topics: Imatinib & Myeloid leukemia. The author has an hindex of 30, co-authored 68 publications receiving 5187 citations. Previous affiliations of Thomas Ernst include Leipzig University & Heidelberg University.
Papers
More filters
Journal ArticleDOI
Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders
Thomas Ernst,Andrew Chase,Andrew Chase,Joannah Score,Joannah Score,Claire Hidalgo-Curtis,Claire Hidalgo-Curtis,Catherine Bryant,Catherine Bryant,Amy V. Jones,Amy V. Jones,Katherine Waghorn,Katherine Waghorn,Katerina Zoi,Fiona M. Ross,Fiona M. Ross,Andreas Reiter,Andreas Hochhaus,Hans G. Drexler,Andrew S Duncombe,Francisco Cervantes,David Oscier,Jacqueline Boultwood,Francis H. Grand,Francis H. Grand,Nicholas C.P. Cross,Nicholas C.P. Cross +26 more
TL;DR: In this article, the finding of homozygous EZH2 mutations in 9 of 12 individuals with 7q acquired uniparental disomy was described, and the mutations resulted in premature chain termination or direct abrogation of histone methyltransferase activity.
Journal ArticleDOI
Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders
Amy V. Jones,Sebastian Kreil,Katerina Zoi,Katherine Waghorn,Claire Curtis,Lingyan Zhang,Joannah Score,Rachel Seear,Andrew Chase,Francis H. Grand,Helen E. White,Christine Zoi,Dimitris Loukopoulos,Evangelos Terpos,Elisavet-Christine Vervessou,Beate Schultheis,Michael Emig,Thomas Ernst,Eva Lengfelder,Rüdiger Hehlmann,Andreas Hochhaus,David Oscier,Richard T. Silver,Andreas Reiter,Nicholas C.P. Cross +24 more
TL;DR: It is concluded that V617F is widespread in MPDs and detection of this acquired mutation is likely to have a major impact on the way patients with MPD are diagnosed, as well as serving as an obvious target for signal transduction therapy.
Journal ArticleDOI
Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet
Simona Soverini,Andreas Hochhaus,Franck E. Nicolini,Franz Gruber,Thoralf Lange,Giuseppe Saglio,Fabrizio Pane,Martin C. Müller,Thomas Ernst,Gianantonio Rosti,Kimmo Porkka,Michele Baccarani,Nicholas C.P. Cross,Nicholas C.P. Cross,Giovanni Martinelli +14 more
TL;DR: Recommendations aimed to rationalize the use of BCR-ABL mutation testing in chronic myeloid leukemia have been compiled by a panel of experts appointed by the European LeukemiaNet (ELN) and European Treatment and Outcome Study and are here reported.
Journal ArticleDOI
Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms.
Francis H. Grand,Claire Hidalgo-Curtis,Thomas Ernst,Katerina Zoi,Christine Zoi,Carolann McGuire,Sebastian Kreil,Amy V. Jones,Joannah Score,Georgia Metzgeroth,David Oscier,Andrew J. Hall,Christian Brandts,Hubert Serve,Andreas Reiter,Andrew Chase,Nicholas C.P. Cross +16 more
TL;DR: It is concluded that acquired, transforming CBL mutations are a novel and widespread pathogenetic abnormality in morphologically related, clinically aggressive MPNs.
Journal ArticleDOI
EZH2 mutational status predicts poor survival in myelofibrosis
Paola Guglielmelli,Flavia Biamonte,Joannah Score,Joannah Score,Claire Hidalgo-Curtis,Claire Hidalgo-Curtis,Francisco Cervantes,Margherita Maffioli,Tiziana Fanelli,Thomas Ernst,Nils Winkelman,Amy V. Jones,Amy V. Jones,Katerina Zoi,Andreas Reiter,Andrew S Duncombe,Laura Villani,Alberto Bosi,Giovanni Barosi,Nicholas C.P. Cross,Nicholas C.P. Cross,Alessandro M. Vannucchi +21 more
TL;DR: EZH2 mutations are independently associated with shorter survival in patients with PMF and in multivariate analysis, survival of PMF patients was predicted by IPSS high-risk category, a < 25% JAK2V617F allele burden, and EZh2 mutation status.